REPL
Replimune Group
Stock NASDAQ – Stock Market Prices, News & Analysis
Replimune Group Inc is a biotechnology company focused on the development of oncolytic therapies for the treatment of cancer.
Replimune Group
REPL
Replimune Group Inc is a biotechnology company focused on the development of oncolytic therapies for the treatment of cancer.
Price history of Replimune Group
Price history of Replimune Group
Performance & Momentum
Fraud Lawsuit Hits Replimune Group
On July 30, 2025, a law firm announced a class action lawsuit alleging fraud against Replimune Group, urging investors to come forward before September 22 to recover potential losses. This legal action could undermine investor confidence and weigh on the stock's future performance, explaining the recent downward trend. As a result, caution is advised before taking a position.
Strategic Analysis
Replimune Group • 2026
Replimune Group Inc positions itself as an innovative biotechnology company focused on the development of oncolytic therapies for cancer treatment, a niche segment with high growth potential but also high risk. Its model relies on differentiated therapeutic approaches aimed at stimulating the anti-tumor immune response.
- Advanced expertise in oncolytic therapies, an emerging field in immuno-oncology
- Portfolio of promising drug candidates in a sector with high added medical value
- Presence in a dynamic and well-funded US market for biotech innovation
- Fragile financial profile typical of biotechs in the early clinical stages
- Stock history marked by high volatility and prolonged declines
Current momentum shows a notable resurgence of interest following a long period of underperformance, suggesting a potential short-term re-evaluation related to upcoming clinical announcements or expected regulatory advancements. However, the positioning remains speculative and requires close monitoring of clinical developments.
Similar stocks to Replimune Group
Recent News
Replimune Group
Federal probe launched into Replimune Group Inc
8 months agoOn July 22, 2025, Holzer & Holzer, LLC announced an investigation into Replimune to verify the company's compliance with federal securities laws. This revelation is concerning and explains the sharp share decline, with the stock dropping nearly 19% in one day. Such regulatory scrutiny could pose significant legal and reputational risks for the company.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
